Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
161-180 of 2,120 trials

Infliximab for Non-Crohn Anal Fistulas

We are studying whether Infliximab can improve healing in patients with complex anal fistulas after surgery. This trial aims to find out if this treatment helps reduce complications and improve recovery.

Anal Fistula>2 yearsEfficacy phase (II)Standard MedicinesGastroenterologyInternal Medicine

Polycythemia Vera: Givinostat vs. Hydroxyurea

We are studying a new treatment called Givinostat for patients with high-risk Polycythemia Vera to see if it works better and is safer than the standard medication, hydroxyurea.

Polycythemia Vera1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

Hydroceles and Spermatoceles: Comparing Sclerotherapy Treatments

We are studying two methods of sclerotherapy to see which one better reduces symptoms and requires fewer follow-up treatments. This trial also looks at pain levels during the procedure with and without local anesthesia.

SpermatoceleHydrocele>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesUrology

Recurrent Prostate Cancer: SpectraCure P18 System Study

We are evaluating a new treatment system using lasers and a drug for men with recurrent prostate cancer. The study aims to ensure safety and effectiveness in targeting and eliminating cancer cells.

Recurrent Prostate CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Lupus in Children: Anifrolumab Study

We are studying the safety and effectiveness of anifrolumab in children and teens with moderate to severe lupus. This trial aims to find the right dose and see how well it works compared to a placebo.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemotePediatricsRheumatology

Patient-Controlled Sedation for Perineal Laceration Repair

We are studying if adding propofol sedation improves comfort for women during the repair of grade I and II obstetric perineal lacerations. This trial aims to see if it reduces pain and discomfort compared to standard care.

Obstetric Perineal Lacerations6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOtolaryngology

B-cell Acute Lymphoblastic Leukemia: UCART22 Treatment Study

We are testing a new engineered T-cell therapy, UCART22, for patients with relapsed or refractory B-ALL. The study aims to evaluate its safety and effectiveness, especially for those who have not responded to other therapies.

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Advanced Hepatobiliary Cancer: New Immunomodulators

We are studying new immunomodulators to see if they can improve treatment outcomes for patients with advanced hepatobiliary cancer. This includes testing their safety and effectiveness alone and with other cancer therapies.

Bile Duct CancerGallbladder CancerHepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyOncology

Alpha-Thalassemia: Luspatercept Treatment Study

We are investigating whether Luspatercept can improve anemia in adults and adolescents with Alpha-thalassemia. The study will also assess the safety of this treatment in younger participants.

Alpha ThalassemiaEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteHematology

Tuberous Sclerosis Complex: mTOR Inhibitor Treatment in Infants

We are studying the effects of a new treatment on brain development in infants with tuberous sclerosis complex. This trial aims to see if the treatment improves cognitive and behavioral outcomes compared to standard care.

Tuberous Sclerosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Breast Cancer Treatment: Tucatinib and Capecitabine

We are studying a combination of tucatinib, capecitabine, and trastuzumab for patients with HER2-positive breast cancer that has spread to the meninges. The goal is to see if this treatment improves survival and quality of life.

HER2-Amplified Metastatic Breast Cancer with Leptomeningeal Metastases>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Small Cell Lung Cancer: Trilaciclib vs Placebo

We are studying whether trilaciclib can improve survival for patients with extensive stage small cell lung cancer receiving chemotherapy. The trial will also assess its effects on tumor response and safety compared to a placebo.

Extensive Stage Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Triple Negative Metastatic Breast Cancer: Sacituzumab Govitecan Study

We are investigating the safety and effectiveness of a new treatment for patients with triple negative metastatic breast cancer whose disease has worsened after prior therapies. This study will help us learn more about how well this treatment works and its safety profile.

Triple Negative Metastatic Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Prostate Cancer: New Treatment Approach with Hormone Therapy

We are studying whether adding short-term hormone therapy to a targeted treatment helps men with recurrent prostate cancer and a limited number of metastases live longer and improve their quality of life.

Oligorecurrent Hormone-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncologyUrology

CAR-T-Cell Treatment for High-Risk Mantle Cell Lymphoma

We are exploring a new CAR-T-cell therapy for patients with untreated high-risk Mantle Cell Lymphoma. The study compares this new approach to the standard treatment to see which is more effective and safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Prostate Cancer: 177Lu-PSMA-617 Treatment Study

We are evaluating whether adding 177Lu-PSMA-617 to standard treatment helps men with metastatic hormone-sensitive prostate cancer who are not responding well to current therapies. The goal is to see if this combination improves survival and disease control.

Hormone-sensitive Metastatic Prostate Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Advanced Colorectal Cancer: Cetuximab with Encorafenib and Binimetinib

We are studying a combination of three medications for patients with BRAF V600E mutated advanced colorectal cancer. The goal is to see if this treatment can help make surgery possible and improve overall health outcomes.

Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Eplontersen for Transthyretin-Mediated Amyloid Cardiomyopathy

We are studying the long-term safety of eplontersen in adults with ATTR-CM. This trial will help us understand how well the treatment is tolerated over an extended period.

Transthyretin-Mediated Amyloid Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Thromboprophylaxis for Advanced Germ Cell Tumors

We are studying a preventive treatment for patients with advanced germ cell tumors undergoing chemotherapy to see if it can help reduce the risk of blood clots. The trial also looks at the safety and cost-effectiveness of this treatment.

Testicular Germ Cell Tumor3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Pelizaeus-Merzbacher Disease: ION356 Treatment Study

We are evaluating the safety of ION356, a new treatment for Pelizaeus-Merzbacher Disease. This study will help us understand how well the treatment is tolerated when administered directly into the spinal fluid.

Pelizaeus-Merzbacher DiseaseSafety phase (I)No PlaceboInvestigational MedicinesNeurology